Biota Pharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 78   

Articles published

BOTA 2.42 +0.04 (1.68%)
price chart
Biota Pharmaceuticals Inc Stock Downgraded (BOTA)
The gross profit margin for BIOTA PHARMACEUTICALS INC is currently lower than what is desirable, coming in at 34.92%. It has decreased significantly from the same period last year.
Related articles »  
Biota Pharmaceuticals Completes Acquisition of Anaconda Pharma
ATLANTA, June 3, 2015 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals (Nasdaq:BOTA) ("Biota" or the "Company") announced today that it has completed the acquisition of Anaconda Pharma, a privately-held biotechnology company based in Paris, France.
Biota Pharmaceuticals to Acquire Anaconda Pharma
ATLANTA, Feb. 26, 2015 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals (Nasdaq:BOTA) (the "Company") announced today that it has entered into a definitive agreement to acquire Anaconda Pharma, a privately-held biotechnology company based in Paris, ...
Biota to Acquire Anaconda Pharma for Up-to-$38M  Genetic Engineering & Biotechnology News
Biota Pharmaceuticals, Inc. (BOTA) Files Form 4 Insider Buying : Anne Vanlent ...
Biota Pharmaceuticals, Inc. (BOTA): Anne Vanlent , director of Biota Pharmaceuticals, Inc. purchased 35,000 shares on Jun 22, 2015.
Biota Pharmaceuticals Director Anne Vanlent Buys 35000 Shares (BOTA)  Dakota Financial News
Insider Buying: Biota Pharmaceuticals Director Anne Vanlent Buys 35000 ...  WKRB News
Biota Pharmaceuticals: A Cash-Rich Biotech With An Expanding Pipeline (BOTA)
Biota Pharmaceuticals (NASDAQ:BOTA) is a biopharmaceutical company focused on the discovery and development of products to prevent and treat potentially life-threatening viral respiratory infectious diseases.
Short Interest Update of Biota Pharmaceuticals, Inc. (NASDAQ:BOTA)
Biota Pharmaceuticals, Inc. (NASDAQ:BOTA) has shown a rise of 37.2% or 16,933 shares in the short positions. The bets have increased to 62,473 shares on June 30,2015 from 45,540 shares on June 15,2015.
Mid Week Pre-Market Information: Broadcom Corp. (BRCM), Biota ...  WallStreet Scope
Biota Pharmaceuticals, Inc. (BOTA) Discloses Form 4 Insider Buying : Exec ...
Biota Pharmaceuticals, Inc. (BOTA) Discloses Insider Transaction. Anne Vanlent , director of Biota Pharmaceuticals, Inc. purchased 35,000 shares on Jun 22, 2015. The Insider buying transaction was disclosed on Jun 24, 2015 to the Securities and ...
What after Joseph Patti's Insider Purchase of Biota Pharmaceuticals Inc ...
Joseph Patti; that is an insider in Biota Pharmaceuticals Inc (NASDAQ:BOTA) 2.30 -0.10 -4.17% who is the latest to obtain shares in the firm for which he is the current CEO.
Biota Pharmaceuticals: Recent Progress Illustrates Buying Opportunity Remains ...
While the termination of the BARDA contract in April 2014 that provided up $231 million for the development of laninamivir octanoate had a substantial negative effect on Biota in 2014 as it took away a source of major funding, the company has made ...
Massive Swings: Biota Pharmaceuticals, Inc. and Amicus Therapeutics, Inc.
Healthcare investors were presented with major movements in two small stocks today: Amicus Therapeutics (NASDAQ: FOLD ) popped almost 21% on strong phase 3 data for a Fabry disease drug, while Biota Pharmaceuticals (NASDAQ: BOTA ) collapsed ...
Related articles »